Stockscreener 앱 받기
10.71
5.39%
-0.61
시간 외 거래:
10.71
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace
KalVista Strengthens Team with Strategic 87,000-Share Option Grant Package - Stock Titan
Where are the Opportunities in (KALV) - news.stocktradersdaily.com
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph
KalVista Set for Key Investor Presentation: What to Expect from Needham Conference - Stock Titan
KONFIDENT-KID trial of sebetralstat is now fully enrolled - Angioedema News
Cantor Fitzgerald maintains Overweight on Kalvista shares By Investing.com - Investing.com Australia
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial - Yahoo Finance
Stifel maintains Buy on Kalvista stock, price target steady at $39 By Investing.com - Investing.com South Africa
Stifel maintains Buy on Kalvista stock, price target steady at $39 - Investing.com Australia
Cantor Fitzgerald maintains Overweight on Kalvista shares - Investing.com
Kalvista stock holds as JMP reiterates $19 target By Investing.com - Investing.com Australia
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Bank of New York Mellon Corp - Defense World
Kalvista stock holds as JMP reiterates $19 target - Investing.com
KalVista completes enrollment for pediatric HAE trial By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial - MarketScreener
KalVista completes enrollment for pediatric HAE trial - Investing.com India
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial - MarketScreener
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $23.80 Average Target Price from Analysts - Defense World
(KALV) Technical Pivots with Risk Controls - news.stocktradersdaily.com
H.C. Wainwright maintains Buy on Kalvista, $20 target By Investing.com - Investing.com Canada
KalVista Pharmaceuticals’ (KALV) Buy Rating Reiterated at HC Wainwright - Armenian Reporter
H.C. Wainwright maintains Buy on Kalvista, $20 target - Investing.com India
KalVista Pharmaceuticals Stock (KALV): Advancements in HAE Treatment and Regulatory Progress - Value the Markets
HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World
Needham & Company LLC Reiterates “Buy” Rating for KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World
Buy Rating for KalVista Pharmaceuticals Driven by Anticipated FDA Approval and Strong Market Position - TipRanks
Sebetralstat provides early, fast relief for HAE attacks: Data - Angioedema News Today
Jefferies cuts Kalvista stock price target to $31 from $33 - Investing.com
Jefferies cuts Kalvista stock price target to $31 from $33 By Investing.com - Investing.com Canada
KalVista Pharmaceuticals Advances Sebetralstat for HAE - TipRanks
KalVista Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Kalvista Pharmaceuticals Inc reports results for the quarter ended January 31Earnings Summary - TradingView
KALVISTA PHARMACEUTICALS Earnings Results: $KALV Reports Quarterly Earnings - Nasdaq
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - Business Wire
Reviewing KalVista Pharmaceuticals (NASDAQ:KALV) and Hillstream BioPharma (NASDAQ:HILS) - Defense World
KalVista Pharmaceuticals CEO sells $79,827 in stock By Investing.com - Investing.com Australia
KalVista Pharmaceuticals CEO sells $79,827 in stock - Investing.com
KalVista Pharmaceuticals CEO Sells Shares to Cover Tax Obligations - TradingView
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema - The Bakersfield Californian
Kalvista Pharmaceuticals Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
10.70%
자본화:
|
볼륨(24시간):